564 related articles for article (PubMed ID: 19447184)
21. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
Johansson M; Carlsson L
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
[TBL] [Abstract][Full Text] [Related]
22. Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.
Sugrue A; Kremen V; Qiang B; Sheldon SH; DeSimone CV; Sapir Y; Striemer BL; Brady P; Asirvatham SJ; Ackerman MJ; Friedman P; Noseworthy PA
Cardiovasc Drugs Ther; 2015; 29(5):433-41. PubMed ID: 26411977
[TBL] [Abstract][Full Text] [Related]
23. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
Isbister GK; Balit CR; Macleod D; Duffull SB
J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
[TBL] [Abstract][Full Text] [Related]
24. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
25. Effects of therapeutic doses of Pregabalin on QTc interval in conscious rabbits.
Alp R; Citil M; Uzun M; Alp S; Topcu B; Uzlu E; Erdogan HM
Eur Rev Med Pharmacol Sci; 2008; 12(4):223-8. PubMed ID: 18727453
[TBL] [Abstract][Full Text] [Related]
26. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
[TBL] [Abstract][Full Text] [Related]
27. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
28. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs.
Batey AJ; Doe CP
J Pharmacol Toxicol Methods; 2002; 48(1):11-9. PubMed ID: 12750037
[TBL] [Abstract][Full Text] [Related]
29. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
Othong R; Devlin JJ; Kazzi ZN
Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
[TBL] [Abstract][Full Text] [Related]
30. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
31. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
[TBL] [Abstract][Full Text] [Related]
32. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
33. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
34. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
35. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
[TBL] [Abstract][Full Text] [Related]
36. Temporal variability of QT interval and changes in T wave morphology in dogs as markers of the clinical risk of drug-induced proarrhythmia.
Hanton G; Yvon A; Racaud A
J Pharmacol Toxicol Methods; 2008; 57(3):194-201. PubMed ID: 18472280
[TBL] [Abstract][Full Text] [Related]
37. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
38. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
39. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
40. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
